Standing in the GAP : To Formulate a Novel Radioimmunotherapy Regime to Improve the Long-Term Outcome in Breast Cancer

Pock, Ho Liam; Bryan, Teo Yi Wei; Hoon, Tan Puay; Iqbal, Jabed; Ching, Linn Yeh; Tee, Goh Yeow; Wai, Tan Kar; Chong, Toh Han; Wee, Ong Kong; Wei, Yeoh Kheng

doi:10.2217/imt-2017-0080

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These abnormal glycans result from incomplete glycosylation and premature sialylation. There are different expression levels of MUC1 –EMA epitopes that can be recognized in prostatic adenocarcinoma tissue compared with healthy cells [ 13 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

The role of epithelial membrane antigen (EMA) overexpression in the prognosis of prostatic adenocarcinoma

Ghalib

Falah

2022

JMedLife

View full text Add to dashboard Cite

Prostatic adenocarcinoma is the second-most common cancer in men and the fifth most common cause of cancer death. Its incidence increases with age; 75% of patients are 65 years and older. The aim of the study was to assess epithelial membrane antigen (EMA) expression in prostatic adenocarcinoma as a poor prognostic marker and its correlation to some pathological parameters. The formalin-fixed, paraffin-surrounded tissue blocks were retrospectively collected from 40 men diagnosed with prostate carcinoma. All cases were collected from Al Hilla Teaching Hospital and some private labs between October 2018 – November 2020, with ages ranging from 30–89 years. Statistical analysis was done using SPSS 22, frequency and percentage were used for categorical data, and Chi-square was used to evaluate connotation between variables. P-value ≤0.05 was significant. The blocks were sectioned for EMA immunohistochemical staining using monoclonal mouse anti-human EMA protein. EMA protein overexpression was detected in 75% (n=30/40) of prostatic adenocarcinoma cases. EMA expression showed no correlation with the patient's age (P=0.09) and a positive correlation with the cancer grade (P=0.003). In prostatic adenocarcinoma patients, EMA could be seen as a potential prognostic predictor for disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%